Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery

September 15, 2011 updated by: Hadassah Medical Organization

Acute liver failure (ALF) results from an abrupt loss of hepatic metabolic and synthetic function and leads to encephalopathy and potentially multi-organ dysfunction. Aetiologies include autoimmune and metabolic diseases, infectious agents and hepatotoxins. Worldwide, infectious hepatitis (A, B and E) is the most common cause. In Western Europe and the USA, ALF is most frequently caused by paracetamol intoxication.

The MBT can produce immediate results to aid in decision making in patients with acute liver disease. Such a test may affect decision-making regarding transplantation in this setting, facilitate appropriate discharge from critical care to other hospital units and to home, provide point of care assessment of therapeutic interventions.

The BreathID can potentially help in determining:

  • Parameter to include patients in transplant list (the UNOS 1A group)
  • Identification that patient deteriorates and needs extended hospitalization/referral to ICU/change in management
  • An addition to the MELD and or other scores to estimate risk in other acute patients
  • Additional information to that of other commonly utilized prognostic scoring systems

The primary end-point of the study is to develop a model to predict deterioration of the liver disease, which incorporates measurements from the MBT along with other potential variables. The data collected will be used to develop a prediction model using data-mining methodology (linear and non-linear regression models, binary trees, neural networks, etc…). The predictive models may include measurements from the MBT, blood test results, as single measurements or as trend over time. The model that will be developed, will attempt to predict the disease deterioration vs. recovery accurately, at an earlier time point than the standard procedure. A threshold will then be determinate based on adequate sensitivity and specificity levels.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

112

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients that are hospitalaized.

Description

Inclusion Criteria:

  1. Adult men or women (>18 years of age).
  2. Acute Liver insult
  3. No evidence of cirrhosis (unless clinical acute Wilsons)
  4. INR > 1.5
  5. Duration of illness < 24 weeks -

Exclusion Criteria:

  1. Patient with any chronic liver disease
  2. Patient has severe congestive heart failure
  3. Patient has severe pulmonary hypertension
  4. Patient has chronic renal insufficiency with severe cardiac disease
  5. Patient has previous surgical bypass surgery for morbid obesity
  6. Patient has extensive small bowel resection
  7. Patient with established extra-hepatic auto-immune disease on long term treatment
  8. Patient is a recipient of any organ transplant (within the last 3 months)- Patient with proven or suspected hepatocellular carcinoma
  9. Patient is pregnant
  10. Patient allergic to paracetamol (such as Tylenol or any other related medications)
  11. Patients in whom oral intake is contra-indicated
  12. Patient, based on the opinion of the investigator, should not be enrolled into this study
  13. Patients or their nominated representative is unwilling to sign informed consent
  14. Patients that are participating in other clinical trials evaluating experimental treatments or procedures, not including observatory trials -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2011

Primary Completion (Anticipated)

December 1, 2012

Study Registration Dates

First Submitted

September 15, 2011

First Submitted That Met QC Criteria

September 15, 2011

First Posted (Estimate)

September 16, 2011

Study Record Updates

Last Update Posted (Estimate)

September 16, 2011

Last Update Submitted That Met QC Criteria

September 15, 2011

Last Verified

September 1, 2011

More Information

Terms related to this study

Other Study ID Numbers

  • ALF-BID-1108-HMO-CTIL

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Liver Failure

3
Subscribe